Strategic partnership struck between Attomarker and EpitogenX

Attomarker, a spinout from the University of Exeter, has signed a co-development agreement with EpitogenX to advance precision immunology diagnostics across multiple diseases, starting from Lyme Disease and Long Lyme.

This partnership helps to unite both companies’ complementary strengths in next-generation antigen engineering and multiplex immunological diagnostics. The objective is to accelerate the development and commercialisation of a new class of precision diagnostics built on Attomarker’s gold nanotechnology test platforms and powered by EpitogenX’s AI-driven epitope discovery and recombinant antigen production.

This agreement covers development across Attomarker’s full technology portfolio, beginning with the Liscar 6 platform and extending to its handheld instrument in development, enabling rapid, quantitative, multiplex immune profiling for a range of conditions where immune dysregulation is central, commencing with Lyme Disease and Long Lyme.

Leveraging Complementary Partnerships

Attomarker’s technology is based on an optical gold nanoparticle array capable of rapid, label-free, multiplex biomarker measurement from tiny blood samples. It is designed to produce laboratory-quality results in minutes and to scale across disease indications including infection, inflammation, endocrine dysfunction and allergy. 

EpitogenX brings deep expertise in AI-driven epitope mapping (EpitoPredikt™) and antigen display (EpitoGen®), enabling discovery of disease-specific biomarkers and production of highly robust recombinant antigens for use in both laboratory and point-of-care assays. 

About Milltrust Ventures

Attomarker is a notable legacy investment from the successfully-exited British Innovation Fund and Milltrust continues to be a committed investor of the firm’s excellent bio-marker detection work through our third fund, the Future Health Fund. 

For anyone that wishes to learn more about our strong body of work in private markets investments and participate alongside us in our enterprising journey (investing in the 3 defining themes of human health, food security, and sustainability), we welcome the chance to discuss the opportunity further. Please get in touch via mv@milltrust.com.